UBS Group AG - ARBUTUS BIOPHARMA CORP ownership

ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 66 filers reported holding ARBUTUS BIOPHARMA CORP in Q3 2020. The put-call ratio across all filers is 1.33 and the average weighting 0.1%.

Quarter-by-quarter ownership
UBS Group AG ownership history of ARBUTUS BIOPHARMA CORP
ValueSharesWeighting
Q3 2023$127,115
-18.9%
62,618
-8.1%
0.00%
Q2 2023$156,784
+41.1%
68,167
+85.9%
0.00%
Q1 2023$111,095
+104.7%
36,665
+57.4%
0.00%
Q4 2022$54,263
+1256.6%
23,289
+1694.2%
0.00%
Q1 2022$4,000
-97.0%
1,298
-96.2%
0.00%
Q4 2021$132,000
-30.2%
34,108
-45.3%
0.00%
Q2 2021$189,000
-22.5%
62,310
-14.8%
0.00%
Q1 2021$244,000
+281.2%
73,115
+307.9%
0.00%
Q4 2020$64,000
+190.9%
17,926
+155.6%
0.00%
Q3 2020$22,000
-96.3%
7,013
-97.8%
0.00%
Q2 2020$590,000
+57.8%
324,292
-12.4%
0.00%
Q1 2020$374,000
-44.7%
370,148
+52.2%
0.00%
Q4 2019$676,000
+138.0%
243,218
+30.7%
0.00%
Q3 2019$284,000
-17.9%
186,124
+11.8%
0.00%
Q2 2019$346,000
+1547.6%
166,409
+2789.5%
0.00%
Q1 2019$21,000
+16.7%
5,759
+25.1%
0.00%
Q4 2018$18,000
+38.5%
4,605
+232.0%
0.00%
Q3 2018$13,000
-95.3%
1,387
-96.3%
0.00%
Q2 2018$276,000
+31.4%
37,762
-10.0%
0.00%
Q1 2018$210,000
-6.2%
41,965
-5.4%
0.00%
Q4 2017$224,000
-31.3%
44,361
-15.6%
0.00%
Q3 2017$326,00052,566
+45609.6%
0.00%
Q2 2017$0
-100.0%
115
-93.8%
0.00%
Q1 2017$6,000
-68.4%
1,854
-66.3%
0.00%
Q3 2016$19,000
-9.5%
5,500
-9.5%
0.00%
Q2 2016$21,000
-12.5%
6,078
+6.0%
0.00%
Q1 2016$24,000
-31.4%
5,733
-28.9%
0.00%
Q4 2015$35,000
-23.9%
8,059
+7.3%
0.00%
Q3 2015$46,0007,5120.00%
Other shareholders
ARBUTUS BIOPHARMA CORP shareholders Q3 2020
NameSharesValueWeighting ↓
Whitefort Capital Management, LP 11,895,477$24,147,81812.66%
Two Seas Capital LP 8,280,818$16,810,0613.38%
FourWorld Capital Management LLC 1,341,907$2,724,0710.51%
Tejara Capital Ltd 180,077$365,5560.21%
Woodline Partners LP 4,719,903$9,581,4030.11%
Hudson Bay Capital Management LP 8,299,808$16,848,6100.07%
Kepos Capital LP 155,691$3160.06%
Virtus ETF Advisers LLC 40,040$81,2810.05%
Centiva Capital, LP 1,071,705$2,175,5610.05%
Kades & Cheifetz LLC 20,000$40,6000.03%
View complete list of ARBUTUS BIOPHARMA CORP shareholders